Compare OVBC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | ENTX |
|---|---|---|
| Founded | 1872 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | OVBC | ENTX |
|---|---|---|
| Price | $38.89 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 15.0K | ★ 208.2K |
| Earning Date | 01-27-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $64,211,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | 11.98 | ★ 25.25 |
| 52 Week Low | $21.86 | $1.50 |
| 52 Week High | $42.00 | $3.22 |
| Indicator | OVBC | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 33.90 |
| Support Level | $38.59 | $1.53 |
| Resistance Level | $40.90 | $1.99 |
| Average True Range (ATR) | 0.94 | 0.19 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 39.29 | 13.79 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.